Literature DB >> 23798682

An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease.

Annalisa Cavallini1, Suzanne Brewerton, Amanda Bell, Samantha Sargent, Sarah Glover, Clare Hardy, Roger Moore, John Calley, Devaki Ramachandran, Michael Poidinger, Eric Karran, Peter Davies, Michael Hutton, Philip Szekeres, Suchira Bose.   

Abstract

Neurofibrillary tangles, one of the hallmarks of Alzheimer disease (AD), are composed of paired helical filaments of abnormally hyperphosphorylated tau. The accumulation of these proteinaceous aggregates in AD correlates with synaptic loss and severity of dementia. Identifying the kinases involved in the pathological phosphorylation of tau may identify novel targets for AD. We used an unbiased approach to study the effect of 352 human kinases on their ability to phosphorylate tau at epitopes associated with AD. The kinases were overexpressed together with the longest form of human tau in human neuroblastoma cells. Levels of total and phosphorylated tau (epitopes Ser(P)-202, Thr(P)-231, Ser(P)-235, and Ser(P)-396/404) were measured in cell lysates using AlphaScreen assays. GSK3α, GSK3β, and MAPK13 were found to be the most active tau kinases, phosphorylating tau at all four epitopes. We further dissected the effects of GSK3α and GSK3β using pharmacological and genetic tools in hTau primary cortical neurons. Pathway analysis of the kinases identified in the screen suggested mechanisms for regulation of total tau levels and tau phosphorylation; for example, kinases that affect total tau levels do so by inhibition or activation of translation. A network fishing approach with the kinase hits identified other key molecules putatively involved in tau phosphorylation pathways, including the G-protein signaling through the Ras family of GTPases (MAPK family) pathway. The findings identify novel tau kinases and novel pathways that may be relevant for AD and other tauopathies.

Entities:  

Keywords:  Alzheimer Disease; Bioinformatics; Enzymes; Glycogen Synthase Kinase 3; Kinase; Phosphorylation; Tau

Mesh:

Substances:

Year:  2013        PMID: 23798682      PMCID: PMC3743503          DOI: 10.1074/jbc.M113.463984

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease.

Authors:  Raymond C C Chang; Ada K Y Wong; Ho-Keung Ng; Jacques Hugon
Journal:  Neuroreport       Date:  2002-12-20       Impact factor: 1.837

3.  Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

Authors:  David E Hurtado; Laura Molina-Porcel; Jenna C Carroll; Caryn Macdonald; Awo K Aboagye; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

4.  Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.

Authors:  Bridget Allen; Esther Ingram; Masaki Takao; Michael J Smith; Ross Jakes; Kanwar Virdee; Hirotaka Yoshida; Max Holzer; Molly Craxton; Piers C Emson; Cristiana Atzori; Antonio Migheli; R Anthony Crowther; Bernardino Ghetti; Maria Grazia Spillantini; Michel Goedert
Journal:  J Neurosci       Date:  2002-11-01       Impact factor: 6.167

5.  Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments.

Authors:  T Maas; J Eidenmüller; R Brandt
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

Review 6.  Tau and axonopathy in neurodegenerative disorders.

Authors:  Makoto Higuchi; Virginia M Y Lee; John Q Trojanowski
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

7.  Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.

Authors:  I Ferrer; R Blanco; M Carmona; B Puig
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

8.  Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.

Authors:  Valérie Buée-Scherrer; Michel Goedert
Journal:  FEBS Lett       Date:  2002-03-27       Impact factor: 4.124

9.  Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis.

Authors:  C Atzori; B Ghetti; R Piva; A N Srinivasan; P Zolo; M B Delisle; S S Mirra; A Migheli
Journal:  J Neuropathol Exp Neurol       Date:  2001-12       Impact factor: 3.685

10.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

View more
  47 in total

Review 1.  What is strain in neurodegenerative diseases?

Authors:  Ye Tian; Lanxia Meng; Zhentao Zhang
Journal:  Cell Mol Life Sci       Date:  2019-09-17       Impact factor: 9.261

2.  Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology.

Authors:  Miranda E Orr; Angelica Salinas; Rochelle Buffenstein; Salvatore Oddo
Journal:  Neurobiol Aging       Date:  2013-12-14       Impact factor: 4.673

3.  Glucocorticoid-mediated activation of GSK3β promotes tau phosphorylation and impairs memory in type 2 diabetes.

Authors:  Aditi Dey; Shuai Hao; Marlena Wosiski-Kuhn; Alexis M Stranahan
Journal:  Neurobiol Aging       Date:  2017-05-19       Impact factor: 4.673

4.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

5.  Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease.

Authors:  T L Platt; T L Beckett; K Kohler; D M Niedowicz; M P Murphy
Journal:  Neuroscience       Date:  2015-12-14       Impact factor: 3.590

Review 6.  Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review.

Authors:  Erwin Lemche
Journal:  Curr Genomics       Date:  2018-11       Impact factor: 2.236

Review 7.  Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease.

Authors:  Angela Jeong; Kiall Francis Suazo; W Gibson Wood; Mark D Distefano; Ling Li
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-06       Impact factor: 8.250

Review 8.  Biological Hallmarks of Cancer in Alzheimer's Disease.

Authors:  Kelly N H Nudelman; Brenna C McDonald; Debomoy K Lahiri; Andrew J Saykin
Journal:  Mol Neurobiol       Date:  2019-04-16       Impact factor: 5.590

9.  Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk.

Authors:  Timothy J Hohman; Jessica N Cooke-Bailey; Christiane Reitz; Gyungah Jun; Adam Naj; Gary W Beecham; Zhi Liu; Regina M Carney; Jeffrey M Vance; Michael L Cuccaro; Ruchita Rajbhandary; Badri Narayan Vardarajan; Li-San Wang; Otto Valladares; Chiao-Feng Lin; Eric B Larson; Neill R Graff-Radford; Denis Evans; Philip L De Jager; Paul K Crane; Joseph D Buxbaum; Jill R Murrell; Towfique Raj; Nilufer Ertekin-Taner; Mark W Logue; Clinton T Baldwin; Robert C Green; Lisa L Barnes; Laura B Cantwell; M Daniele Fallin; Rodney C P Go; Patrick Griffith; Thomas O Obisesan; Jennifer J Manly; Kathryn L Lunetta; M Ilyas Kamboh; Oscar L Lopez; David A Bennett; John Hardy; Hugh C Hendrie; Kathleen S Hall; Alison M Goate; Rosalyn Lang; Goldie S Byrd; Walter A Kukull; Tatiana M Foroud; Lindsay A Farrer; Eden R Martin; Margaret A Pericak-Vance; Gerard D Schellenberg; Richard Mayeux; Jonathan L Haines; Tricia A Thornton-Wells
Journal:  Alzheimers Dement       Date:  2015-06-16       Impact factor: 21.566

10.  Short Fibrils Constitute the Major Species of Seed-Competent Tau in the Brains of Mice Transgenic for Human P301S Tau.

Authors:  Samuel J Jackson; Caroline Kerridge; Jane Cooper; Annalisa Cavallini; Benjamin Falcon; Claire V Cella; Alessia Landi; Philip G Szekeres; Tracey K Murray; Zeshan Ahmed; Michel Goedert; Michael Hutton; Michael J O'Neill; Suchira Bose
Journal:  J Neurosci       Date:  2016-01-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.